Fearon, Douglas Thomas

Publications

Sort by

Co-Author Network

selected publications

Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack. Proceedings of the National Academy of Sciences of the United States of America. 2022 Academic Article GET IT
Times cited: 16
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells. British journal of cancer. 2021 Comment GET IT
Times cited: 8
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proceedings of the National Academy of Sciences of the United States of America. 2020 Academic Article GET IT
Times cited: 92
Cancer cell CCR2 orchestrates suppression of the adaptive immune response. The Journal of experimental medicine. 2020 Academic Article GET IT
Times cited: 24
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020 Academic Article GET IT
Times cited: 457
A framework for advancing our understanding of cancer-associated fibroblasts. Nature reviews. Cancer. 2020 Review GET IT
Times cited: 1374
Embryonic FAP⁺ lymphoid tissue organizer cells generate the reticular network of adult lymph nodes. The Journal of experimental medicine. 2019 Academic Article GET IT
Times cited: 31
Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 88
Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature. 2019 Academic Article GET IT
Times cited: 401
Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science (New York, N.Y.). 2018 Academic Article GET IT
Times cited: 684
Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science (New York, N.Y.). 2018 Academic Article GET IT
Times cited: 135
Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature medicine. 2018 Review GET IT
Times cited: 2512
Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 65
Stromal Cells in the Tumor Microenvironment. Advances in experimental medicine and biology. 2018 Review GET IT
Times cited: 163
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Academic Article GET IT
Times cited: 679
Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. The oncologist. 2017 Academic Article GET IT
Times cited: 4
Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Letter GET IT
Times cited: 22
Connecting the Metabolic and Immune Responses to Cancer. Trends in molecular medicine. 2017 Review GET IT
Times cited: 51
Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. Cold Spring Harbor symposia on quantitative biology. 2017 Academic Article GET IT
Times cited: 4
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. The Journal of experimental medicine. 2017 Academic Article GET IT
Times cited: 1185
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell metabolism. 2016 Academic Article GET IT
Times cited: 207
Combination immunotherapy for cancer. The Journal of experimental medicine. 2016 Comment GET IT
Times cited: 4
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer immunology research. 2016 Conference Paper GET IT
Times cited: 23
T cell exclusion, immune privilege, and the tumor microenvironment. Science (New York, N.Y.). 2015 Review GET IT
Times cited: 1376
Classification of current anticancer immunotherapies. Oncotarget. 2014 Review GET IT
Times cited: 340
Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer research. 2014 Academic Article GET IT
Times cited: 236
Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1. Cancer immunology, immunotherapy : CII. 2014 Academic Article GET IT
Times cited: 14
Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 90
The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 193
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 1225
Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1. Cancer immunology research. 2013 Academic Article GET IT
Times cited: 102
Transcriptional regulation of effector and memory CD8+ T cell fates. Current opinion in immunology. 2013 Review GET IT
Times cited: 26
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 237
Tumour immunology. Current opinion in immunology. 2013 Editorial Article GET IT
Times cited: 5
Control of HIV infection: escape from the shadow of Blimp-1. European journal of immunology. 2013 Academic Article GET IT
Times cited: 8
Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 57
Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 52
siRNA high-throughput kinase library screen identifies protein kinase, DNA-activated catalytic polypeptide to play a role in MyD88-induced IFNA2 activation and IL-8 secretion. Biotechnology and applied biochemistry. 2012 Academic Article GET IT
Times cited: 1
T-bet-mediated differentiation of the activated CD8+ T cell. European journal of immunology. 2010 Academic Article GET IT
Times cited: 28
Cutting edge: Virus-specific CD8+ T cell clones and the maintenance of replicative function during a persistent viral infection. Journal of immunology (Baltimore, Md. : 1950). 2010 Academic Article GET IT
Times cited: 10
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (New York, N.Y.). 2010 Academic Article GET IT
Times cited: 823
Pillars Article: CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science, 1992. 256: 105-107. Journal of immunology (Baltimore, Md. : 1950). 2010 Review GET IT
Times cited: 4
Does pre-hospital telephone communication with a clinician result in more appropriate medication administration by parents during childhood asthma exacerbations?. The Journal of asthma : official journal of the Association for the Care of Asthma. 2009 Academic Article GET IT
Times cited: 4
The precursors of memory: models and controversies. Nature reviews. Immunology. 2009 Academic Article GET IT
Times cited: 145
Pathways of memory CD8+ T-cell development. European journal of immunology. 2009 Review GET IT
Times cited: 42
Secondary replicative function of CD8+ T cells that had developed an effector phenotype. Science (New York, N.Y.). 2009 Academic Article GET IT
Times cited: 134
Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation. 2008 Editorial Article GET IT
Times cited: 124
Loss of T cell receptor-induced Bmi-1 in the KLRG1(+) senescent CD8(+) T lymphocyte. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 67
The expansion and maintenance of antigen-selected CD8(+) T cell clones. Advances in immunology. 2007 Review GET IT
Times cited: 27
CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiation. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 50
Identifying genes important for spermatogonial stem cell self-renewal and survival. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 342
The rationale for the IL-2-independent generation of the self-renewing central memory CD8+ T cells. Immunological reviews. 2006 Review GET IT
Times cited: 25
The proto-oncogene BCL-6 is expressed in olfactory sensory neurons. Neuroscience research. 2005 Academic Article GET IT
Times cited: 11
BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 68
Bcl-6 uncouples B lymphocyte proliferation from differentiation. Advances in experimental medicine and biology. 2002 Review GET IT
Times cited: 6
Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science (New York, N.Y.). 2001 Review GET IT
Times cited: 226
IgM and stromal cell-associated heparan sulfate/heparin as complement-independent ligands for CD19. European journal of immunology. 2001 Academic Article GET IT
Times cited: 29
Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. The Journal of experimental medicine. 2000 Academic Article GET IT
Times cited: 201
Enhanced immunogenicity of aldehyde-bearing antigens: a possible link between innate and adaptive immunity. European journal of immunology. 2000 Academic Article GET IT
Times cited: 68
Innate immunity--beginning to fulfill its promise?. Nature immunology. 2000 Comment GET IT
Times cited: 27
Receptor modulators of B-cell receptor signalling--CD19/CD22. Current topics in microbiology and immunology. 2000 Review GET IT
Times cited: 33
Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annual review of immunology. 2000 Review GET IT
Times cited: 431
Innate immunity and the biological relevance of the acquired immune response. QJM : monthly journal of the Association of Physicians. 1999 Editorial Article GET IT
Times cited: 8
Transplanted hepatocytes infected with a complement receptor type 1 (CR1)-containing recombinant adenovirus are resistant to hyperacute rejection. Transplantation proceedings. 1999 Academic Article GET IT
Times cited: 5
The complement system and adaptive immunity. Seminars in immunology. 1998 Review GET IT
Times cited: 109
Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. Journal of immunology (Baltimore, Md. : 1950). 1998 Academic Article GET IT
Times cited: 92
CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity. 1998 Academic Article GET IT
Times cited: 164
Inhibition of the B cell by CD22: a requirement for Lyn. The Journal of experimental medicine. 1998 Academic Article GET IT
Times cited: 226
Non-structural determinants of immunogenicity and the B cell co-receptors, CD19, CD21, and CD22. Advances in experimental medicine and biology. 1998 Review GET IT
Times cited: 5
Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. The Journal of experimental medicine. 1997 Academic Article GET IT
Times cited: 62
Seeking wisdom in innate immunity. Nature. 1997 Comment GET IT
Times cited: 201
Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Immunity. 1997 Academic Article GET IT
Times cited: 107
Happy coupling: recruiting both antigen and effector function. Nature biotechnology. 1997 Article GET IT
Times cited: 6
Co-receptors of B lymphocytes. Current opinion in immunology. 1997 Review GET IT
Times cited: 63
Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex. Journal of immunology (Baltimore, Md. : 1950). 1997 Academic Article GET IT
Times cited: 70
The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene. 1997 Academic Article GET IT
Times cited: 45
Innate pathways that control acquired immunity. Current opinion in immunology. 1997 Editorial Article GET IT
Times cited: 84
Construction, function and in vivo expression of a complement receptor type 1 containing recombinant adenovirus for use in xenotransplantation. Transplantation proceedings. 1997 Academic Article GET IT
Times cited: 2
The signaling activity of murine CD19 is regulated during cell development. Journal of immunology (Baltimore, Md. : 1950). 1996 Academic Article GET IT
Times cited: 96
Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Current opinion in immunology. 1996 Review GET IT
Times cited: 51
The instructive role of innate immunity in the acquired immune response. Science (New York, N.Y.). 1996 Review GET IT
Times cited: 1441
Complement: instructing the acquired immune system through the CD21/CD19 complex. Research in immunology. 1996 Review GET IT
Times cited: 15
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (New York, N.Y.). 1996 Academic Article GET IT
Times cited: 1029
A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors. The Journal of experimental medicine. 1996 Academic Article GET IT
Times cited: 191
Self-renewal of B-1 lymphocytes is dependent on CD19. European journal of immunology. 1996 Academic Article GET IT
Times cited: 113
CD28-mediated costimulation in the absence of phosphatidylinositol 3-kinase association and activation. Molecular and cellular biology. 1995 Academic Article GET IT
Times cited: 63
A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science (New York, N.Y.). 1995 Academic Article GET IT
Times cited: 490
Through the glass lightly. Science (New York, N.Y.). 1995 Academic Article GET IT
Through the glass lightly. Science (New York, N.Y.). 1995 Academic Article GET IT
The B lymphocyte as an immunotherapeutic target. QJM : monthly journal of the Association of Physicians. 1995 Review GET IT
Times cited: 2
The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annual review of immunology. 1995 Review GET IT
Times cited: 435
Binding of C3b and C4b by the CR1-like site in murine CR1. Journal of immunology (Baltimore, Md. : 1950). 1994 Academic Article GET IT
Times cited: 24
Innate immunity: 50 ways to kill a microbe. Current opinion in immunology. 1994 Editorial Article GET IT
Times cited: 16
Therapeutic uses of recombinant complement protein inhibitors. Springer seminars in immunopathology. 1994 Review GET IT
Times cited: 50
Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. The Journal of experimental medicine. 1993 Academic Article GET IT
Times cited: 197
A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proceedings of the National Academy of Sciences of the United States of America. 1993 Academic Article GET IT
Times cited: 133
The CD19-CR2-TAPA-1 complex, CD45 and signaling by the antigen receptor of B lymphocytes. Current opinion in immunology. 1993 Review GET IT
Times cited: 67
CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science (New York, N.Y.). 1993 Academic Article GET IT
Times cited: 284
Human anti-endotoxin antibody HA-1A mediates complement-dependent binding of Escherichia coli J5 lipopolysaccharide to complement receptor type 1 of human erythrocytes and neutrophils. The Journal of infectious diseases. 1993 Academic Article GET IT
Times cited: 19
Effect of repetitive doses of soluble human complement receptor type 1 on survival of discordant cardiac xenografts. Transplantation proceedings. 1993 Academic Article GET IT
Times cited: 15
CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science (New York, N.Y.). 1992 Academic Article GET IT
Times cited: 561
Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Transplantation proceedings. 1992 Academic Article GET IT
Times cited: 22
Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. The Journal of experimental medicine. 1991 Academic Article GET IT
Times cited: 68
Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor. The Journal of experimental medicine. 1991 Academic Article GET IT
Times cited: 74
The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. Journal of immunology (Baltimore, Md. : 1950). 1991 Academic Article GET IT
Times cited: 106
Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science (New York, N.Y.). 1991 Academic Article GET IT
Times cited: 209
Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors. Clinical and experimental immunology. 1991 Review GET IT
Times cited: 38
Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. Journal of immunology (Baltimore, Md. : 1950). 1991 Academic Article GET IT
Times cited: 68
Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. The Journal of experimental medicine. 1991 Academic Article GET IT
Times cited: 92
Tyrosine phosphorylation of phospholipase C induced by membrane immunoglobulin in B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 1991 Academic Article GET IT
Times cited: 165
Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. The Journal of experimental medicine. 1991 Academic Article GET IT
Times cited: 264
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (New York, N.Y.). 1990 Academic Article GET IT
Times cited: 876
Complement receptor type 1 (C3b/C4b receptor; CD35) and complement receptor type 2 (C3d/Epstein-Barr virus receptor; CD21). Current topics in microbiology and immunology. 1990 Review GET IT
Times cited: 42
Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21). Immunodeficiency reviews. 1990 Review GET IT
Times cited: 35
Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Transactions of the Association of American Physicians. 1990 Academic Article GET IT
Times cited: 71
Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. The Journal of experimental medicine. 1989 Academic Article GET IT
Times cited: 122
Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM. Journal of immunology (Baltimore, Md. : 1950). 1989 Academic Article GET IT
Times cited: 57
Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. The Journal of experimental medicine. 1989 Academic Article GET IT
Times cited: 82
Immunoregulatory functions of complement: structural and functional studies of complement receptor type 1 (CR1; CD35) and type 2 (CR2; CD21). Progress in clinical and biological research. 1989 Academic Article GET IT
Times cited: 8
Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Advances in immunology. 1989 Review GET IT
Times cited: 387
Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor. Proceedings of the National Academy of Sciences of the United States of America. 1988 Academic Article GET IT
Times cited: 40
Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. The Journal of experimental medicine. 1988 Academic Article GET IT
Times cited: 206
Complement, C receptors, and immune complex disease. Hospital practice (Office ed.). 1988 Review GET IT
Times cited: 10
Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. Journal of immunology (Baltimore, Md. : 1950). 1988 Academic Article GET IT
Times cited: 212
Selective synthesis of mRNA and proteins by human peripheral blood neutrophils. Journal of immunology (Baltimore, Md. : 1950). 1988 Academic Article GET IT
Times cited: 81
Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1. The Journal of experimental medicine. 1988 Academic Article GET IT
Times cited: 100
Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. The Journal of experimental medicine. 1988 Academic Article GET IT
Times cited: 89
Hereditary angioedema: a decade of management with stanozolol. The Journal of allergy and clinical immunology. 1987 Academic Article GET IT
Times cited: 66
Neutrophil activation after burn injury: contributions of the classic complement pathway and of endotoxin. Surgery. 1987 Academic Article GET IT
Times cited: 37
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987 Academic Article GET IT
Times cited: 349
Expansion of the complement receptor gene family. Identification in the mouse of two new genes related to the CR1 and CR2 gene family. Journal of immunology (Baltimore, Md. : 1950). 1987 Academic Article GET IT
Times cited: 26
Deficiency of the C3b/C4b receptor (CR1) of erythrocytes in systemic lupus erythematosus: analysis of the stability of the defect and of a restriction fragment length polymorphism of the CR1 gene. Journal of immunology (Baltimore, Md. : 1950). 1987 Academic Article GET IT
Times cited: 65
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. The Journal of experimental medicine. 1987 Academic Article GET IT
Times cited: 193
A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. Journal of immunology (Baltimore, Md. : 1950). 1987 Academic Article GET IT
Times cited: 94
CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review. Immunologic research. 1987 Review GET IT
Times cited: 20
Cellular distribution of complement receptor type 4 (CR4): expression on human platelets. Journal of immunology (Baltimore, Md. : 1950). 1987 Academic Article GET IT
Times cited: 38
Human receptor for C3b/C4b: complement receptor type I. Methods in enzymology. 1987 Academic Article GET IT
Differential interaction of the C3b/C4b receptor and MHC class I with the cytoskeleton of human neutrophils. Journal of immunology (Baltimore, Md. : 1950). 1986 Academic Article GET IT
Times cited: 14
Analysis of multiple restriction fragment length polymorphisms of the gene for the human complement receptor type I. Duplication of genomic sequences occurs in association with a high molecular mass receptor allotype. The Journal of experimental medicine. 1986 Academic Article GET IT
Times cited: 32
Purification of the B lymphocyte receptor for the C3d fragment of complement and the Epstein-Barr virus by monoclonal antibody affinity chromatography, and assessment of its functional capacities. Journal of immunological methods. 1986 Academic Article GET IT
Times cited: 11
Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement. Proceedings of the National Academy of Sciences of the United States of America. 1986 Academic Article GET IT
Times cited: 51
Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. The Journal of experimental medicine. 1986 Academic Article GET IT
Times cited: 147
Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis and rheumatism. 1986 Academic Article GET IT
Times cited: 144
Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. The New England journal of medicine. 1986 Academic Article GET IT
Times cited: 132
Decreased expression of C3b receptor (CR1) on erythrocytes of patients with systemic lupus erythematosus contrasts with its normal expression in other systemic diseases and does not correlate with the occurrence or severity of SLE nephritis. Complement (Basel, Switzerland). 1986 Academic Article GET IT
Times cited: 13
The role of receptors for complement in the induction of polyclonal B-cell proliferation and differentiation. Journal of clinical immunology. 1986 Academic Article GET IT
Times cited: 19
Tissue-specific phosphorylation of complement receptors CR1 and CR2. The Journal of experimental medicine. 1986 Academic Article GET IT
Times cited: 71
The identification of N-linked oligosaccharides on the human CR2/Epstein-Barr virus receptor and their function in receptor metabolism, plasma membrane expression, and ligand binding. The Journal of biological chemistry. 1985 Academic Article GET IT
Times cited: 21
Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proceedings of the National Academy of Sciences of the United States of America. 1985 Academic Article GET IT
Times cited: 54
Rapid purification of the human C3b/C4b receptor (CR1) by monoclonal antibody affinity chromatography. Journal of immunological methods. 1985 Academic Article GET IT
Times cited: 23
Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus. 1985 GET IT
Times cited: 41
Human complement receptors for C3b (CR1) and C3d (CR2). The Journal of investigative dermatology. 1985 Academic Article GET IT
Times cited: 18
Acquired deficiency of the inhibitor of the first component of complement: report of five additional cases with commentary on the syndrome. 1985 GET IT
Times cited: 61
p65: A C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor. Journal of immunology (Baltimore, Md. : 1950). 1985 Academic Article GET IT
Times cited: 53
Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. Journal of immunology (Baltimore, Md. : 1950). 1985 Academic Article GET IT
Times cited: 90
Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3. Journal of immunology (Baltimore, Md. : 1950). 1985 Academic Article GET IT
Times cited: 50
PMA induces the ligand-independent internalization of CR1 on human neutrophils. Journal of immunology (Baltimore, Md. : 1950). 1985 Academic Article GET IT
Times cited: 66
Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria. Journal of immunology (Baltimore, Md. : 1950). 1985 Academic Article GET IT
Times cited: 8
Altered expression of complement receptors as a pathogenetic factor in systemic lupus erythematosus. Arthritis and rheumatism. 1984 Academic Article GET IT
Times cited: 40
Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney international. 1984 Academic Article GET IT
Times cited: 205
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proceedings of the National Academy of Sciences of the United States of America. 1984 Academic Article GET IT
Times cited: 689
Structure and function of the human C3b receptor. Federation proceedings. 1984 Academic Article GET IT
Times cited: 7
Altered surface distribution of both C3b receptors and Fc receptors on neutrophils induced by anti-C3b receptor or aggregated IgG. Journal of immunology (Baltimore, Md. : 1950). 1984 Academic Article GET IT
Times cited: 31
Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan. Journal of immunology (Baltimore, Md. : 1950). 1984 Academic Article GET IT
Times cited: 15
Cellular receptors for fragments of the third component of complement. Immunology today. 1984 Academic Article GET IT
Times cited: 64
Increased expression of the C3b receptor by neutrophils and complement activation during haemodialysis. Clinical and experimental immunology. 1984 Academic Article GET IT
Times cited: 55
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 1984 Academic Article GET IT
Times cited: 192
Characterization of human T lymphocytes that express the C3b receptor. Journal of immunology (Baltimore, Md. : 1950). 1983 Academic Article GET IT
Times cited: 80
Genetic regulation of a structural polymorphism of human C3b receptor. The Journal of clinical investigation. 1983 Academic Article GET IT
Times cited: 81
Continuing medical education. This continuing medical education self-assessment program is sponsored by the American Academy of Allergy and Immunology and supported by a grant-in-aid from Fisons Corporation. The Journal of allergy and clinical immunology. 1983 Academic Article GET IT
Expression of C3b receptors on human be cells and myelomonocytic cells but not natural killer cells. Journal of immunology (Baltimore, Md. : 1950). 1983 Academic Article GET IT
Times cited: 68
Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. Journal of immunology (Baltimore, Md. : 1950). 1983 Academic Article GET IT
Times cited: 144
Endocytosis of the C3b receptor of complement within coated pits in human polymorphonuclear leukocytes and monocytes. Laboratory investigation; a journal of technical methods and pathology. 1983 Academic Article GET IT
Times cited: 43
Complement ligand-receptor interactions that mediate biological responses. Annual review of immunology. 1983 Review GET IT
Times cited: 193
Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. Journal of immunology (Baltimore, Md. : 1950). 1983 Academic Article GET IT
Times cited: 341
The human C3b receptor. Springer seminars in immunopathology. 1983 Review GET IT
Times cited: 37
The role of antibody in the activation of the alternative complement pathway. Springer seminars in immunopathology. 1983 Review GET IT
Times cited: 81
Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. The New England journal of medicine. 1982 Academic Article GET IT
Times cited: 215
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. Journal of immunology (Baltimore, Md. : 1950). 1982 Academic Article GET IT
Times cited: 450
Lipid monolayer-coated solid surfaces do not perturb the lateral motion and distribution of C3b receptors on neutrophils. The Journal of cell biology. 1982 Academic Article GET IT
Times cited: 19
Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus. The Journal of clinical investigation. 1982 Academic Article GET IT
Times cited: 139
Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. Journal of immunology (Baltimore, Md. : 1950). 1982 Academic Article GET IT
Times cited: 26
Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. The Journal of allergy and clinical immunology. 1981 Academic Article GET IT
Times cited: 91
Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes. The Journal of experimental medicine. 1981 Academic Article GET IT
Times cited: 58
IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. Journal of immunology (Baltimore, Md. : 1950). 1981 Academic Article GET IT
Times cited: 33
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. The Journal of clinical investigation. 1981 Academic Article GET IT
Times cited: 140
Lateral distribution and diffusion of the C3b receptor of complement, HLA antigens, and lipid probes in peripheral blood leukocytes. Proceedings of the National Academy of Sciences of the United States of America. 1980 Academic Article GET IT
Times cited: 56
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. The New England journal of medicine. 1980 Academic Article GET IT
Times cited: 116
Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. The Journal of experimental medicine. 1980 Academic Article GET IT
Times cited: 446
Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin. Journal of immunology (Baltimore, Md. : 1950). 1980 Academic Article GET IT
Times cited: 56
Activation of the alternative complement pathway. CRC Critical reviews in immunology. 1979 Review GET IT
Times cited: 44
Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proceedings of the National Academy of Sciences of the United States of America. 1979 Academic Article GET IT
Times cited: 335
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. The Journal of experimental medicine. 1979 Academic Article GET IT
Times cited: 146
Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. The Journal of allergy and clinical immunology. 1979 Academic Article GET IT
Times cited: 27
[Alternative complement pathway (author's transl)]. La Nouvelle presse medicale. 1979 Review GET IT
Times cited: 3
Action of the C3b-inactivator on the cell-bound C3b. Journal of immunology (Baltimore, Md. : 1950). 1979 Academic Article GET IT
Times cited: 79
A molecular basis of activation of the alternative pathway of human complement. Advances in experimental medicine and biology. 1979 Review GET IT
Times cited: 20
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. Journal of immunology (Baltimore, Md. : 1950). 1979 Academic Article GET IT
Times cited: 271
Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway. Proceedings of the National Academy of Sciences of the United States of America. 1978 Academic Article GET IT
Times cited: 31
Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes. Proceedings of the National Academy of Sciences of the United States of America. 1978 Academic Article GET IT
Times cited: 33
Inhibition of the alternative pathway of complement by gold sodium thiomalate in vitro. Journal of immunology (Baltimore, Md. : 1950). 1978 Academic Article GET IT
Times cited: 20
Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor. Journal of immunology (Baltimore, Md. : 1950). 1978 Academic Article GET IT
Times cited: 59
Opsonin-independent phagocytosis of activators of the alternative complement pathway by human monocytes. Journal of immunology (Baltimore, Md. : 1950). 1978 Academic Article GET IT
Times cited: 78
Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proceedings of the National Academy of Sciences of the United States of America. 1978 Academic Article GET IT
Times cited: 311
The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins. Journal of immunology (Baltimore, Md. : 1950). 1978 Academic Article GET IT
Times cited: 41
Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. The Journal of experimental medicine. 1978 Academic Article GET IT
Times cited: 142
Purification of C3b inactivator and demonstration of its two polypeptide chain structure. Journal of immunology (Baltimore, Md. : 1950). 1977 Academic Article GET IT
Times cited: 55
The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function. Journal of immunology (Baltimore, Md. : 1950). 1977 Academic Article GET IT
Times cited: 37
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. The Journal of experimental medicine. 1977 Academic Article GET IT
Times cited: 122
Tranexamic acid: preoperative prophylactic therapy for patients with hereditary angioneurotic edema. The Journal of allergy and clinical immunology. 1977 Academic Article GET IT
Times cited: 40
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proceedings of the National Academy of Sciences of the United States of America. 1977 Academic Article GET IT
Times cited: 202
Methyltestosterone therapy in hereditary angioedema. Annals of internal medicine. 1977 Academic Article GET IT
Times cited: 48
Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection. Transplantation proceedings. 1977 Review GET IT
Times cited: 21
Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B. Immunology. 1976 Academic Article GET IT
Times cited: 11
Control of the amplification convertase of complement by the plasma protein beta1H. Proceedings of the National Academy of Sciences of the United States of America. 1976 Academic Article GET IT
Times cited: 448
C3 requirements for formation of alternative pathway C5 convertase. Journal of immunology (Baltimore, Md. : 1950). 1976 Academic Article GET IT
Times cited: 70
Editorial: Glomerulonephritis, complement and C3NeF. The New England journal of medicine. 1976 Academic Article GET IT
Times cited: 5
Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF). Journal of immunology (Baltimore, Md. : 1950). 1976 Academic Article GET IT
Times cited: 16
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. Journal of immunology (Baltimore, Md. : 1950). 1976 Academic Article GET IT
Times cited: 185
The natural modulation of the amplification phase of complement activation. Transplantation reviews. 1976 Review GET IT
Times cited: 20
Initiation of C3 cleavage in the alternative complement pathway. Journal of immunology (Baltimore, Md. : 1950). 1975 Academic Article GET IT
Times cited: 35
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. The Journal of experimental medicine. 1975 Academic Article GET IT
Times cited: 317
Properdin: initiation of alternative complement pathway. Proceedings of the National Academy of Sciences of the United States of America. 1975 Academic Article GET IT
Times cited: 54
Inhibition of complement-derived enzymes. Annals of the New York Academy of Sciences. 1975 Review GET IT
Times cited: 6
Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. The New England journal of medicine. 1975 Academic Article GET IT
Times cited: 126
Depressed synovial fluid levels of properdin and properdin factor B in patients with rheumatoid arthritis. Arthritis and rheumatism. 1975 Academic Article GET IT
Times cited: 25
The properdin pathway: mechanisms of complement activation and analogies to the classical pathway. Rheumatology. 1975 Review GET IT
Times cited: 3
Properdin factor D. II. Activation to D by properdin. The Journal of experimental medicine. 1974 Academic Article GET IT
Times cited: 28
Properdin factor D: characterization of its active site and isolation of the precursor form. The Journal of experimental medicine. 1974 Academic Article GET IT
Times cited: 81
The functional significance of complement. Advances in nephrology from the Necker Hospital. 1974 Review GET IT
Times cited: 8
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. The Journal of experimental medicine. 1973 Academic Article GET IT
Times cited: 102
Serum proteins involved in decay and regeneration of cobra venom factor-dependent complement activation. Journal of immunology (Baltimore, Md. : 1950). 1973 Academic Article GET IT
Times cited: 10

more ...

less ...

Background

education and training

M.D., The Johns Hopkins University School of Medicine 1968
B.A., Williams College 1964

Contact

full name

Douglas Thomas Fearon

primary email

dof2014@med.cornell.edu

VIVO Weill Cornell Medical College

Douglas Thomas Fearon Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email